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The gene for human cathepsin H is located on 
chromosome 15q24-q25 and contains 12 exons 
spanning over 23 kb of genomic sequences. The 
junctions between the exons and 11 introns conform t  
the GT-AG rule. The preproenzyme transcript length is 
1005 bp. 
Transcription 
The cathepsin H gene has a TATA- and CAAT-less 
promoter and upstream of exon 1 only one GC box was 
detected, suggesting the presence of one more exon. 
Two different forms of cathepsin H cDNA, the full-
length form (CTSH) and a truncated form with deletion 
of 12 amino acids at the signal peptide region 
(CTSHdelta10-21), were identified in prostate tissues 
and cancer cell lines. 
Protein 
Description 
Cathepsin H belongs to the superfamily of papain-like 
cysteine proteases. It is synthesized as a preproenzyme 
of 335 amino acid residues with a calculated Mr of 37 
403. It is proteolytically processed to an active single 
chain, i.e. mature form within the 
endosomes/lysosomes. A unique feature of this enzyme 
is that it acts as both an aminopeptidase and an 
endopeptidase although the latter activity is much 
lower than the former activity. Sequencing data 
revealed that in addition to the heavy and light chains, 
which are typically found in a number of mammalian 
papain-like cysteine proteases, cathepsin H contains 
also an octapeptide EPQNCSAT originating from the 
propeptide, termed the mini-chain. It was shown that 
the mini-chain is disulfide linked to Cys205 of the main 
body of the enzyme and involved in the aminopeptidase 
activity of the enzyme. It was concluded that the mini-
chain plays a key role in substrate recognition, and that 
the carbohydrate residues attached to the body of the 
enzyme are involved in the positioning the mini-chain 
in the active-site cleft. Procathepsin H has three 
potential carbohydrate binding sites. Glycosilation has 
been confirmed on Asn230 and on the mini-chain 
Asn101 of the mature enzyme. The recombinant form 
of human cathepsin H lacking the mini-chain was 
shown to be an endopeptidase. Cathepsin H hidrolyzes 
endopeptidase substrates such as Bz-Arg+NHNap, Bz-
Arg+NHMec, Bz-Phe-Val-Arg+NHMec, and acts on 
Pro-Gly+Phe and Pro-Arg+NHNap much like a 
dipeptidyl-peptidase. It was shown to cleave several 
proteins preferring hydrophobic residues at P2 and P3, 
however the endopeptidase activity of the enzyme is 
limited. Collagen and laminin, for instance, were not 
degraded by cathepsin H. Naturally occurring inhibitors 
of cathepsin H are the cystatins, a2-macroglobulin and
antigens from mouse cytotoxic lymphocytes CTLA-2β. 
Expression 
Cathepsin H expression is ubiquitous, with very high 
expression in the kidney. There is growing evidence 
that the expression of cathepsin H is increased in 
diseases including breast, colorectal and prostate 
carcinoma, melanoma and gliomas. In contrast, 
decreased cathepsin H expression has been reported in 
squamous cell carcinoma of the head and neck. Other 
studies have found a higher cathepsin H expression in 
well-differentiated pancreatic cancer cells compared 
with less well-differentiated cancer cells. 
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Richardson diagram of cathepsin H structure: a-helixes are shown in red and β -sheets in green. Catalytic residues are shown in ball-
and-stick representation: Cys141 in yellow, His281 in purple and Asn301 in pink. Carbohydrates are shown as CPK spheres in yellow. 
The mini chain is shown in grey (MEROPS: the peptidase database - C01.040). 
Localisation 
Cathepsin H is located manly at the endosomal-
lysosomal compartments. Only 10% of the enzyme is 
secreted. It has been shown that substantial 
concentrations of cathepsin H circulate in the blood. 
Function 
Cathepsin H is one of the lysosomal cysteine 
proteinases, which are involved in intracellular protein 
degradation. It is one of the few noncomplement 
proteases that cleave native C5 to generate the potent 
chemotaxin C5a. Cathepsin H was detected in 
extracellular compartments of atherosclerotic plaques. 
Although the pathogenic potential of cathepsin H in the 
development of the late, unstable plaque is quite 
evident, there is the possibility that this protease may 
play a role in early atherogenesis. Furthermore, it was 
found that cathepsin H could contribute to the 
transformation of LDL in monocyte-derived foam cells. 
Recently the enzyme was shown to be essential in one 
of the processing steps of hydrophobic surfactant-
associated protein C. 
Cathepsin H is overexpressed in different tumour cells. 
However, the role of cathepsin H in tumour progression 
is not well understood. A possible function of cathepsin 
H in tumour progression is its ability to degrade 
fibrinogen and fibronectin, suggesting that, along with 
other proteases, cathepsin H may be involved in the 
destruction of extracellular matrix components leading 
to cancer proliferation, migration, and metastasis. 
Homology 
Cathepsins H exhibit a high degree of sequence 
homology to cathepsin B and other cysteine proteinases 
of the C1 (papain) family. 
Mutations 
Germinal 
Not yet reported 
Somatic 




Protein levels of cathepsin H were measured by ELISA 
in preoperative sera from 324 patients with colorectal 
cancer. The level of cathepsin H was significantly 
increased in patient sera, the median level was 8.4 
ng/mL versus 2.1 ng/mL in 90 healthy blood donors (p 
< 0.0001). In survival analysis a significant difference 
was found between the group of patients with low 
cathepsin H (first tertile) who had a poor prognosis and 
the remaining patients (p = 0.03). The risk of patients 
was further stratified when cathepsin H levels were 
combined with carcinoembryonic antigen (CEA). 
Patients with high CEA and low cathepsin H had the 
highest risk of death with a hazard ratio of 2.72 (95% 
CI 1.73-4.28), p < 0.0001.The prognostic information 
of cathepsin H differs from that of the related 
cathepsins B and L and suggest different roles during 
the progression of malignant disease. 
Melanoma 
Prognosis 
The level of cathepsin H was determined in the seraof 
43 patients with metastatic melanoma, in 54 patients  
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with treated cutaneous melanoma with no evidence of 
metastatic disease, and in 30 healthy blood donors, 
using quantitative ELISA. The levels were significantly 
higher within the group of metastatic melanoma 
patients compared with the healthy controls with a 
median of 13.7 versus 4.9 ng/ml (P < 0.0001). 
Cathepsin H was also significantly increased within e 
group of melanoma patients with no metastasis, witha 
median of 9.6 ng/ml. The serum level was increased in 
patients showing no response to the 
chemoimmunotherapy as compared to the level in 
responders. Metastatic melanoma patients with high 
content of cathepsin H experienced significantly shorter 
overall survival rates than the patients with low levels 
of the enzyme (Cat H: P < 0.006 and relative risk, 2.4
using median as cut-off value). 
Head and neck carcinoma 
Prognosis 
To estimate the prognostic value of cathepsins H in 
head and neck carcinoma, its concentration was 
measured in cytosols of primary tumours and adjacent 
normal tissue from 21 patients. Cathepsin H 
concentration was higher in normal tissue (p = 0.001) 
than in tumour tissue and in laryngeal than in non-
laryngeal normal and tumour tissues. Disease-free 
survival was poor in patients with lower concentrations 
of cathepsin H in tumour tissue (p = 0.055). 
Bladder cell transitional cell carcinoma 
Note: Using spectrofluorometric assay, catalytic 
activity of cathepsin H was measured in human bladder 
cell lines (HCV29, normal; RT4, well differentiated; 
J82, poorly differentiated) and in noncancerous and 
cancerous tissue samples (n = 20) of transitional cell 
carcinoma. In comparison to the intracellular activity of 
cathepsin H in the poorly differentiated cell line J82, 
the intracellular activity in the normal cell line HCV29 
was significantly greater (P <0.05), independent of 
stage or grade. In contrast, the portion of cathepsin H 
released from cell line J82 into the supernatant, 
revealed higher values than that from cell line HCV29. 
In cancerous bladder tissue, the level of cathepsin H 
was significantly greater than in the matched normal 
tissue (P <0.05). 
Lung cancer 
Note: A transgenic mouse model of lung cancer was 
utilized to identify markers of early lung tumours in 
humans. Immunohistochemical analyses identified 
cathepsin H as being consistently elevated in the 
murine lung tumours compared to non-tumour bearing 
transgenic lung tissue surrounding the tumour. 
Importantly, the elevation was observed in early stage, 
indicating its ability to detect early lung lesions that 
would be amenable to surgical resection. 
Glioma 
Note: Cathepsin H activity was determined in normal 
brain tissue and tumour tissue extracts. The activity of 
cathepsin H was twofold higher in low grade glioma, 
fourfold higher in anaplastic astrocytoma and eightfold 
higher in glioblastoma than in normal brain tissue. 
Cathepsin H antibody inhibited the invasion of 
glioblastoma cell lines through Matrigel®. These data 
suggest that the tumour-specific increase in antige 
may be a useful independent marker of tumour 
progression in central nervous system neoplasms. 
Cervical carcinoma 
Note: The expression of cathepsin H in cervical 
carcinoma cell lines and tissue was found to be down-
regulated compared to normal tissue, using cDNA 
arrays. 
Joint diseases 
Note: The level of cathepsin H was determined in 
synovial fluids and sera of patients with inflammatory 
and metabolic joint diseases, using quantitative ELISA. 
Cathepsin H was not found in normal sera (values 
below 3 micrograms/l), but was measurable in patients' 
synovial fluids. The highest values of cathepsin H were 
measured in synovial fluids of patients with 
undifferentiated arthritis. There is yet no clear 
correlation between the quantity of the enzyme released 
in synovia and the clinical diagnosis or the stage of 
disease. 
Alzheimer's disease 
Note: Cultured fibroblasts from patients affected by 
Alzheimer's disease (AD) exhibited alterations of the 
enzyme transketolase. Abnormalities (dubbed alkaline 
band) consisted of enzyme forms having unusually 
high pl and were proposed as a marker of the disease in 
living patients. Human cathepsin H was shown to 
partially induce an Alzheimer-like transketolase pattern 
and cleave normal transketolase to a 35 kDa fragment 
as spontaneously occurring in Alzheimer's disease 
fibroblasts. The explanation of transketolase 
abnormalities could be an imbalance of proteolysis in 
Alzheimer's disease fibroblasts due to a relative 
increase/derangement of cysteine proteinases, includi g 
cathepsin H. 
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